Shatavari Root Extract for Perimenopause: RCT (Int J Women's Health 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: International Journal of Women's Health (Dove Medical Press) · Published: August 26, 2026 · Accessed: August 27, 2026

Visit the source ↗

Claims this source supports

• In a randomized, double-blind, placebo-controlled trial of 80 perimenopausal women aged 40-55 (73 completed), 300 mg/day of standardized Shatavari (Asparagus racemosus) root extract (SRI-81) for eight weeks significantly improved menopausal symptom scores on the Menopause Rating Scale compared with placebo.
• Total MRS scores decreased 42.6% from baseline in the shatavari group versus 5.5% in the placebo group; perceived stress scores declined almost 30% from baseline, and hot-flash scores decreased 26% versus 7% with placebo.
• Shatavari supplementation was also associated with improvements in fatigue and vigor measures.
• No adverse events were reported during the trial; liver and kidney function markers remained stable across the eight weeks.
• The trial studied perimenopausal women only; the authors state that trials in menopausal (postmenopausal) women are needed to establish efficacy beyond the perimenopausal population.